Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma

Alaa Fayed, David G. Mutch, Janet S. Rader, Randall K. Gibb, Matthew A. Powell, Jason D. Wright, Issam ElNaqa, Imran Zoberi, Perry W. Grigsby

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Purpose: To compare the outcomes for endometrial carcinoma patients treated with either high-dose-rate (HDR) or low-dose-rate (LDR) brachytherapy. Methods and Materials: This study included 1,179 patients divided into LDR (1,004) and HDR groups (175). Patients with International Federation of Gynecology and Obstetrics (FIGO) surgical Stages I-III were included. All patients were treated with postoperative irradiation. In the LDR group, the postoperative dose applied to the vaginal cuff was 60-70 Gy surface doses to the vaginal mucosa. The HDR brachytherapy prescription was 6 fractions of 2 Gy each to a depth of 0.5 cm from the surface of the vaginal mucosa. Overall survival, disease-free survival, local control, and complications were endpoints. Results: For all stages combined, the overall survival, disease-free survival, and local control at 5 years in the LDR group were 70%, 69%, and 81%, respectively. For all stages combined, the overall survival, disease-free survival, and local control at 5 years in the HDR group were 68%, 62%, and 78%, respectively. There were no significant differences in early or late Grade III and IV complications in the HDR or LDR groups. Conclusion: Survival outcomes, pelvic tumor control, and Grade III and IV complications were not significantly different in the LDR brachytherapy group compared with the HDR group.

Original languageEnglish
Pages (from-to)480-484
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume67
Issue number2
DOIs
StatePublished - Feb 1 2007

Keywords

  • Brachytherapy
  • Endometrial cancer
  • HDR
  • LDR

Fingerprint Dive into the research topics of 'Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma'. Together they form a unique fingerprint.

  • Cite this